ASP Isotopes (Nasdaq: ASPI) is advancing commercial production at its three South African facilities, with Silicon-28—critical for quantum computing—now producing at over 80 kg/year, far exceeding original estimates. Ytterbium-176 is also ramping up, with semi-continuous production set to begin in August. The company is expanding into Carbon-12, accelerating enrichment plans for Nickel-64, Gadolinium-160, and Zinc-68, and preparing for a QLE spinout and Renergen acquisition later this year.

Lantern Pharma (Nasdaq: LTRN) has unveiled a cutting-edge AI module within its RADR® platform to predict the efficacy, safety, and biomarker profiles of DNA-damaging agent (DDA) and DNA damage response inhibitor (DDRi) combinations—targeting the $50B+ and growing cancer combination therapy market. Trained on 221 clinical trials, the module has already guided the FDA-cleared trial design for LP-184 + olaparib in triple-negative breast cancer, and is set to streamline future precision oncology regimens by slashing costs and accelerating development timelines.

XTI Aerospace (Nasdaq: XTIA) has appointed Charlie Burgoyne—AI innovator and CENTCOM advisor—to its Corporate Advisory Board, deepening its national security capabilities as it advances its TriFan 600 xVTOL platform and prepares for future unmanned systems. Burgoyne’s expertise in real-time, AI-powered decision systems strengthens XTI’s push into defense, autonomy, and next-gen aerial mobility, aligning with U.S. policy priorities on domestic drone and VTOL production.

bioAffinity Technologies (Nasdaq: BIAF) released a compelling case study showcasing how its noninvasive CyPath® Lung test identified Stage 1A lung cancer in a high-risk patient with inconclusive imaging and low modeled malignancy risk. With 92% sensitivity and reimbursed access, CyPath® Lung is emerging as a vital tool for early detection—especially when traditional diagnostics fall short.